Proliferation and Survival Signaling from Both Jak2-V617F and Lyn Involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 Cell Line Newly Established from Acute Myeloid Leukemia Transformed from Polycythemia Vera

The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: Therapeutic implications

(2013) Alfonso Quintás-Cardama   LEUKEMIA RESEARCH

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms

(2013) Costanza Bogani et al.   PLoS One

GSK-3 and mitochondria in cancer cells

(2013) Federica Chiara et al.   Frontiers in Oncology

Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management

(2012) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Functions of the Lyn tyrosine kinase in health and disease

(2012) Evan Ingley   Cell Communication and Signaling

JAK2 the future: therapeutic strategies for JAK-dependent malignancies

(2012) Lindsay M. LaFave et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis

(2011) Yusuke Takeda et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy

(2011) P J Shami et al.   LEUKEMIA

DNA Damage Stress and Inhibition of Jak2-V617F Cause Its Degradation and Synergistically Induce Apoptosis through Activation of GSK3β

(2011) Toshikage Nagao et al.   PLoS One

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

(2010) N Chapuis et al.   LEUKEMIA

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia

(2009) J. Tamburini et al.   BLOOD

Sorafenib Induces Apoptosis Specifically in Cells Expressing BCR/ABL by Inhibiting Its Kinase Activity to Activate the Intrinsic Mitochondrial Pathway

(2009) T. Kurosu et al.   CANCER RESEARCH

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

(2008) Ji Wu et al.   JNCI-Journal of the National Cancer Institute